Molecular Partners Ag (MOLN) Cash & Equivalents (2020 - 2026)

Molecular Partners Ag (MOLN) has reported Cash & Equivalents for 7 consecutive years, with $82048.8 the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 100.0% year-over-year to $82048.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82048.8 (down 100.0% YoY) and the FY2025 annual result came in at $103.41, down 100.0% from the prior year.
• Cash & Equivalents rose to $82048.8 in Q1 2026 per MOLN's latest filing, from $103.41 in the prior quarter.
• Over the last five years, Cash & Equivalents for MOLN reached as high as $153.8 billion in Q1 2022 and fell as low as $99.02 in Q2 2025.
• A 5-year average of $37.0 billion and a median of $91.3 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents rose 17.22% — and 2026, when it sank 100.0%.
• Year by year, Cash & Equivalents stood at $91.3 million in 2022, then retreated by 16.88% to $75.9 million in 2023, then retreated by 3.91% to $72.9 million in 2024, then plunged by 100.0% to $103.41 in 2025, then jumped by 79240.97% to $82048.8 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $82048.8, $103.41, and $102957.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.